• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

同源和异源加强接种对原始 SARS-CoV-2 B.1、P.1、C.37 和 B.1.617.2 变异株诱导的中和反应。

Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants.

机构信息

Instituto de Virología "Dr. J. M. Vanella", Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.

Instituto de Virología "Dr. J. M. Vanella", Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.

出版信息

Vaccine. 2022 Nov 8;40(47):6706-6710. doi: 10.1016/j.vaccine.2022.10.021. Epub 2022 Oct 20.

DOI:10.1016/j.vaccine.2022.10.021
PMID:36280564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9581801/
Abstract

Heterologous Covid-19 vaccination strategies arose due to interruption of vaccination programs plus delay and shortage of vaccine supplies. We analysed neutralizing response against ancestral SARS-CoV-2 B.1 and P.1, C.37 and B.1.67.2 variants elicited by 16 homologous and heterologous protocols combining Gam-COVID-Vac, ChAdOx1-S, Ad5-nCorV, BBIBP-CorV and mRNA-1273 vaccines. Homologous mRNA-1273 and heterologous schemes of a non-replicative viral vector/inactivated virus-based vaccine combined with mRNA-1273 induced significantly broader and greater neutralizing antibody-response. Moreover, serum from participants vaccinated with combinations of ChAdOx1-S/Ad5-nCorV and BBIBP-CorV/non-replicative viral vector-based vaccines showed higher or equivalent neutralizing response compared to homologous protocols, pointing them as good alternative platforms. BBIBP-CorV used as second dose exhibited significantly lower neutralizing response compared to other protocols, demonstrating that it should not be recommended as second dose. The information provided herein is valuable to redesign vaccination strategies, especially for low-income countries that still struggle with low percentages of immunized populations and vaccine supply shortage.

摘要

由于疫苗接种计划中断以及疫苗供应延迟和短缺，出现了异源 COVID-19 疫苗接种策略。我们分析了由 Gam-COVID-Vac、ChAdOx1-S、Ad5-nCorV、BBIBP-CorV 和 mRNA-1273 疫苗组合的 16 种同源和异源方案引发的针对原始 SARS-CoV-2 B.1 和 P.1、C.37 和 B.1.67.2 变体的中和反应。同源的 mRNA-1273 和异源的非复制性病毒载体/灭活病毒疫苗与 mRNA-1273 相结合的方案诱导了更广泛和更强的中和抗体反应。此外，接种 ChAdOx1-S/Ad5-nCorV 和 BBIBP-CorV/非复制性病毒载体疫苗组合的参与者的血清显示出比同源方案更高或相当的中和反应，表明它们是良好的替代平台。与其他方案相比，作为第二剂使用的 BBIBP-CorV 表现出明显较低的中和反应，表明不建议将其作为第二剂使用。本文提供的信息对于重新设计疫苗接种策略非常有价值，特别是对于那些仍在努力提高免疫人口比例和应对疫苗供应短缺的低收入国家。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b8/9581801/0979bff94731/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b8/9581801/0979bff94731/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b8/9581801/0979bff94731/gr1_lrg.jpg

相似文献

1
Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants.同源和异源加强接种对原始 SARS-CoV-2 B.1、P.1、C.37 和 B.1.617.2 变异株诱导的中和反应。
Vaccine. 2022 Nov 8;40(47):6706-6710. doi: 10.1016/j.vaccine.2022.10.021. Epub 2022 Oct 20.
2
Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.使用 Sputnik V、ChAdOx1-S、BBIBP-CorV、Ad5-nCoV 和 mRNA-1273 进行异源 SARS-CoV-2 免疫接种的免疫原性和反应原性。
Cell Rep Med. 2022 Aug 16;3(8):100706. doi: 10.1016/j.xcrm.2022.100706. Epub 2022 Aug 3.
3
Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.COVID-19 基础-加强免疫接种的安全性和有效性：同源 BBIBP-CorV 与异源 BNT162b2 加强剂在 BBIBP-CorV 基础免疫人群中的效果。
Vaccine. 2023 Mar 17;41(12):1925-1933. doi: 10.1016/j.vaccine.2023.01.032. Epub 2023 Jan 23.
4
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.新型冠状病毒灭活疫苗（Vero 细胞）作为异源加强针免疫原性和安全性的研究：一项 2 期临床试验。
Signal Transduct Target Ther. 2022 Jun 6;7(1):172. doi: 10.1038/s41392-022-00984-2.
5
Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines.针对 SARS-CoV-2 的中和广度与异源初免-加强疫苗接种顺序的关联。
Med. 2022 Aug 12;3(8):568-578.e3. doi: 10.1016/j.medj.2022.05.003. Epub 2022 Jun 9.
6
Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.BBIBP-CORV 疫苗加强针针对 SARS-CoV-2 关切变异株的免疫应答。
J Clin Virol. 2022 Jun;150-151:105161. doi: 10.1016/j.jcv.2022.105161. Epub 2022 Apr 12.
7
Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.从匈牙利血清学人类样本中比较 COVID 疫苗的免疫激活：ChAdOx1、BNT162b2、mRNA-1273、BBIBP-CorV 和 Gam-COVID-Vac 显示基于 mRNA 的免疫接种后具有更高的保护作用。
Eur Rev Med Pharmacol Sci. 2022 Jul;26(14):5297-5306. doi: 10.26355/eurrev_202207_29321.
8
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.异源加强免疫 PastoCovac Plus 对 ChAdOx1-S 或 BBIBP-CorV 初免个体的 COVID-19 免疫原性和安全性。
PLoS Pathog. 2023 Nov 1;19(11):e1011744. doi: 10.1371/journal.ppat.1011744. eCollection 2023 Nov.
9
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.异源初免-加强接种灭活 COVID-19 疫苗和 ChAdOx1 nCoV-19（AZD1222）疫苗的免疫原性和反应原性：一项准实验研究。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2206360. doi: 10.1080/21645515.2023.2206360. Epub 2023 May 4.
10
Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.转向蛋白质：基于蛋白质的 NVX-CoV2373 作为灭活和病毒载体 COVID-19 疫苗异源加强针的免疫原性和安全性。
Expert Rev Vaccines. 2023 Jan-Dec;22(1):620-628. doi: 10.1080/14760584.2023.2232020.

引用本文的文献

1
Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine.BBIBP-CorV灭活疫苗联合BNT62b2 mRNA加强疫苗的疗效评估
Diagnostics (Basel). 2023 Feb 2;13(3):556. doi: 10.3390/diagnostics13030556.
2
An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight.关注植物化学物质对 SARS-CoV-2 的预防和治疗选择：分子视角。
Molecules. 2023 Jan 13;28(2):795. doi: 10.3390/molecules28020795.

本文引用的文献

1
Adopting an heterologous prime-boost strategy in COVID-19 vaccination: the need for locally generated evidence in Africa.在 COVID-19 疫苗接种中采用异源初免-加强策略：非洲需要产生本地证据。
Pan Afr Med J. 2022 Feb 18;41:148. doi: 10.11604/pamj.2022.41.148.31620. eCollection 2022.
2
Optimizing COVID-19 vaccination programs during vaccine shortages.在疫苗短缺期间优化新冠疫苗接种计划。
Infect Dis Model. 2022 Mar;7(1):286-298. doi: 10.1016/j.idm.2022.02.002. Epub 2022 Feb 25.
3
Vaccine apartheid: global cooperation and equity.
疫苗种族隔离：全球合作与公平
Lancet. 2022 Apr 16;399(10334):1452-1453. doi: 10.1016/S0140-6736(22)00328-2. Epub 2022 Feb 23.
4
Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination.异源 ChAdOx1/mRNA-1273 疫苗接种诱导广泛的抗 SARS-CoV-2 抗体免疫。
Science. 2022 Mar 4;375(6584):1041-1047. doi: 10.1126/science.abn2688. Epub 2022 Feb 10.
5
Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials.在低收入和中等收入国家使用替代疫苗平台应对疫苗短缺所引发的免疫原性：两项随机临床试验的结果
Lancet Reg Health Am. 2022 May;9:100196. doi: 10.1016/j.lana.2022.100196. Epub 2022 Feb 2.
6
Equitable access to COVID-19 vaccines makes a life-saving difference to all countries.公平获取 COVID-19 疫苗对所有国家都有着生死攸关的意义。
Nat Hum Behav. 2022 Feb;6(2):207-216. doi: 10.1038/s41562-022-01289-8. Epub 2022 Jan 31.
7
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
8
Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.评估 Gam-COVID-Vac 疫苗和针对 SARS-CoV-2 谱系 P.1 变异株的疫苗诱导的中和反应在阿根廷队列中的表现。
Vaccine. 2022 Jan 31;40(5):811-818. doi: 10.1016/j.vaccine.2021.12.027. Epub 2021 Dec 20.
9
Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine.第三剂 BNT162b2 mRNA 疫苗的有效性。
J Infect Dis. 2022 Jan 5;225(1):30-33. doi: 10.1093/infdis/jiab556.
10
Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.异源 ChAdOx1-BNT162b2 疫苗接种的免疫原性和疗效。
Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21.